Roflumilast to reduce Ketamine-Induced Cognitive Deficits

• Research type

  Research Study

• Full title

  A Randomized, Double-Blind, Placebo Controlled, Three-period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast on Preventing Ketamine-Induced Cognitive Deficits as well as Brain Electrical Activity Changes in Healthy Adults.

• IRAS ID

  110974

• Contact name

  Paul Morrison

• Sponsor organisation

  Nycomed-a Takeda Company

• Eudract number

  2012-002065-35

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  Schizophrenia is a chronic, mental disorder that affects about 1 percent of people throughout the world. It typically begins in adolescence and early adulthood. It causes impairment in cognition ie attention, working memory, decision making, it removes inhibitions and causes hallucinations and delusions. It is thought that fluilast may improve the impairment of mental processes seen in Schizophrenia. In this study a drug called Ketamine will be used to induce symptoms that closely resemble those of patients with schizophrenia and fluilast will then be given to determine what impact it has on these symptoms.

• REC name

  London - Riverside Research Ethics Committee

• REC reference

  12/LO/1308

• Date of REC Opinion

  13 Nov 2012

• REC opinion

  Further Information Favourable Opinion